Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.
Completed
Janssen Sciences Ireland UC
Phase 2
The purpose of this study is to evaluate the antiviral effect of repeated oral dosing of JNJ
53718678 compared to placebo in healthy adult participants infected through inoculation with
respiratory syncytial virus (RSV)-A Memphis 37b virus.
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants
Completed
Janssen Sciences Ireland UC
Phase 1
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of
three dosages (250, 500, and 1000 milligram [mg], or maximum tolerated dose [MTD]) of JNJ
53718678 when administered as single dose in fasting conditions in healthy Japanese adult
participants in 3 cohorts.
Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants
Completed
Janssen Sciences Ireland UC
Phase 1
The primary objective is to evaluate in a double-blinded (neither physician nor participant
knows the treatment that the participant receives), fashion the taste of different
JNJ-53718678 oral liquid formulations as compared to the reference formulation (JNJ-53718678,
10 milligram/milliliter oral solution without sweetener/flavor).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
